SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:ba33b7f4-7705-43ed-9eb6-538a70bb0048"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:ba33b7f4-7705-43ed-9eb6-538a70bb0048" > Prospective Safety ...

  • Hartman, Mark L (författare)

Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients.

  • Artikel/kapitelEngelska2013

Förlag, utgivningsår, omfång ...

  • The Endocrine Society,2013
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:ba33b7f4-7705-43ed-9eb6-538a70bb0048
  • https://lup.lub.lu.se/record/3438403URI
  • https://doi.org/10.1210/jc.2012-2684DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Context:In clinical practice, the safety profile of GH replacement therapy for GH-deficient adults compared with no replacement therapy is unknown.Objective:The objective of this study was to compare adverse events (AEs) in GH-deficient adults who were GH-treated with those in GH-deficient adults who did not receive GH replacement.Design and Setting:This was a prospective observational study in the setting of US clinical practices.Patients and Outcome Measures:AEs were compared between GH-treated (n = 1988) and untreated (n = 442) GH-deficient adults after adjusting for baseline group differences and controlling the false discovery rate. The standardized mortality ratio was calculated using US mortality rates.Results:After a mean follow-up of 2.3 years, there was no significant difference in rates of death, cancer, intracranial tumor growth or recurrence, diabetes, or cardiovascular events in GH-treated compared with untreated patients. The standardized mortality ratio was not increased in either group. Unexpected AEs (GH-treated vs untreated, P ≤ .05) included insomnia (6.4% vs 2.7%), dyspnea (4.2% vs 2.0%), anxiety (3.4% vs 0.9%), sleep apnea (3.3% vs 0.9%), and decreased libido (2.1% vs 0.2%). Some of these AEs were related to baseline risk factors (including obesity and cardiopulmonary disease), higher GH dose, or concomitant GH side effects.Conclusions:In GH-deficient adults, there was no evidence for a GH treatment effect on death, cancer, intracranial tumor recurrence, diabetes, or cardiovascular events, although the follow-up period was of insufficient duration to be conclusive for these long-term events. The identification of unexpected GH-related AEs reinforces the fact that patient selection and GH dose titration are important to ensure safety of adult GH replacement.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Xu, Rong (författare)
  • Crowe, Brenda J (författare)
  • Robison, Leslie L (författare)
  • Erfurth, Eva MarieLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-ee0 (författare)
  • Kleinberg, David L (författare)
  • Zimmermann, Alan G (författare)
  • Woodmansee, Whitney W (författare)
  • Cutler, Gordon B (författare)
  • Chipman, John J (författare)
  • Melmed, Shlomo (författare)
  • Medicin, LundSektion II (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical Endocrinology and Metabolism: The Endocrine Society98:3, s. 980-9881945-71970021-972X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy